Drug Profile

TB 201

Alternative Names: TB-201

Latest Information Update: 01 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Peptron; Therabest Korea
Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 Jun 2026 Preclinical trials in Solid tumours in South Korea (Parenteral) (Peptron Pipeline, May 2026)
01 Jun 2026 Preclinical trials in Triple-negative-breast-cancer in South Korea (Parenteral) (Peptron Pipeline, May 2026)
29 Dec 2022 Early research in Triple-negative-breast-cancer in South Korea (Parenteral) (Therabest Korea pipeline, December 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com